As a global pharmaceutical company with a biotech mindset and a proven ability to provide new, life-changing therapies, Ipsen is a leading player in its core therapeutic areas.

Contact us


Craig Marks Adrien Dupin de Saint-Cyr
Vice President, Investor Relations Investor Relations Manager
+44 7584 349 193 +33 6 64 26 17 49

Contact us

Ipsen to acquire Epizyme, expanding its portfolio in oncology


Conference call

A conference call and webcast for investors and analysts will begin today at 2pm Paris time.

Participants can join the call by dialling +1 785 424 1876 or, for U.S. participants, +1 877 888 4312 toll-free;

the passcode is 63710.


Ipsen to acquire Epizyme, expanding its portfolio in oncology

Ipsen in Brief

Ipsen in Brief 2022

Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.


Registration document

2021 Universal Registration Document

This registration document contains forward-looking statements about Ipsen’s targets and forecasts, including the Annual Financial Report. The registration document provides a comprehensive information about the Company its activities, financial information, colleagues and legal information


Research & Development pipeline

Ipsen R&D has a valuable pipeline encompassing both lifecycle management of our well-established products, and the development of innovative new molecules.

Learn more

We are focused on accelerating our sales growth while improving our profitability and cash flow generation, in order to further invest in business development to build an innovative and sustainable pipeline and to maintain the growth momentum of the business.

Aymeric Le Chatelier, CFO
© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2022